Professionals 232 Users Online

Trichomonas Rapid Testing Market

Rise in the sexually transmitted infections and growing awareness for early diagnosis of Trichomoniasis to drive the global market

Trichomonas Rapid Testing Market by Product (Cassette Rapid Test Kit, Rapid Test Strip, Rapid test Swab and Molecule based rapid test device)

Trichomonas Rapid Testing Market Outlook (2023 to 2033)

The Global revenue from the Trichomonas Rapid Testing Market stands at US$ 420.9 Million in 2022, with the global market expected to grow at a CAGR of 5.1% to reach a valuation of around US$ 724.5 Million by the end of 2033.

Market Size (2023)

US$ 442.4 Million

Projected Market Value (2033)

US$ 724.5 Million

Global Market Growth Rate (2023 to 2033)

5.1% CAGR

Market Share of Top 5 Countries


As assessed by Persistence Market Research, rapid test strips held a market share of around 37.8% in the global market, in 2022. The global trichomonas rapid testing market holds nearly 11.1% revenue share of the global sexually transmitted disease diagnostic market valued at US$ 3.8 Billion in 2022

Sample Report

FREE Report Sample is Available

In-depth report coverage is now just a few seconds away

Download PDF Get FREE Report Sample

Sales Analysis of Market from 2014 to 2022 Vs Market Outlook for 2023 to 2033

The global market recorded a historic CAGR of 4.1% in the last 8 years from 2014 to 2022.

The most prevalent, treatable, and non-critical sexually transmitted infection (STD) is trichomoniasis. Trichomonas vaginalis, a protozoan parasite, is the culprit. But, men will not demonstrate any indications in this diseases. Women, on the other hand, may exhibit signs like vaginal discharge, genital irritation, burning, or redness if they are infected.

The overall expansion of the worldwide trichomonas rapid testing market is being positively impacted by a number of reasons. The fact that these testing kits are quite simple to use is what is most responsible for the rising demand for this kits. In addition, the trichomonas rapid testing kits are less expensive and need less time to complete than earlier kits. Such benefits have also contributed in lifting up the overall growth of the trichomonas testing industry.

A wide selection of products for trichomonas rapid testing are now available on the market due to the innovation and improvements in the diagnostics sector, particularly in the detection of difficult-to-detect sexually transmitted diseases (STDs) like trichomonas.

The global market is likely to show high growth over the coming years at a CAGR of 5.1% and reach a global market size of 724.5 Million by 2033.

Custom Report Cover

Make This Report Your Own

Take Advantage of Intelligence Tailored to your Business Objective

> Get a Customized Version

How Can the Global Market Grow?

“Rising Prevalence of STD including Trichomoniasis, coupled with Advances in Diagnosis”

Globally, STIs have a substantial influence on reproductive and sexual health. More than 1 million STIs, most of which are asymptomatic, are contracted around the world every day.

  • According to a survey conducted by the World Health Organisation in 2022, there are projected to be 374 million new cases of one of the four curable STIs, such as chlamydia, gonorrhoea, syphilis, and trichomoniasis. World Health Organization (WHO) predicted that there would be 156 million trichomoniasis cases worldwide in 2020. Hence, the market for trichomonas fast testing will develop more rapidly as the number of patients with trichomonas infections increases globally.

Due to recent advancements in trichomoniasis research and the accessibility of trichomonas fast testing kits, it has been shown that the once-overlooked infection of trichomoniasis is now linked to numerous major health risks, particularly in women. In response to such circumstances, manufacturers are developing rapid test kits that are simple to use, inexpensive, and have a quick turnaround time.

  • On July 11, 2022, DynaLIFE put into practise the Aptima Trichomonas vaginalis molecular assay for TV diagnosis in adult females. This requires a different collection device from the present microscopy-based approach.
  • The Artus T. vaginalis QS-RGQ Kit, a CE-marked molecular-based test, was recently introduced on March 5, 2018 by QIAGEN in Europe for the rapid identification of the parasite T. vaginalis in both male and female patients.

The demand for trichomonas fast testing kits that are easy to use, cheap, and have minimal turnaround time can establish a lucrative opportunity for the industry. Manufacturers should provide point-of-care devices that are suitable for both home and professional use in order to meet the needs of healthcare professionals and patients.

Also, a larger sales staff is projected to increase the trichomonas rapid testing products' market penetration through distribution and partnership arrangements. These chances will push the market's expansion for trichomonas quick testing.

Market Research Methodology

Market Research Methodology

-Perfect through Years of Diligence

Check Research Methodology

Can the Market Growth Be Affected in Any Way?

"Lack of Symptom Indications and Undiagnosed Patients"

According to reports, between 70% and 85% of persons with trichomoniasis show little to no outward symptoms, and untreated infections can persist for months or even years. Also, compared to infected women, infected persons are less probable to exhibit any symptoms, according to some research.

Besides the high incidence infection rate, the disease remains untreated due to the high asymptomatic patient’s percentage. Such factors are anticipated to negatively impede the market for trichomonas quick testing and may even reduce its growth rate.

Sales Team

Sales Team
Client Partner

Let's Connect

Connect me to identify winning opportunities

Ask An Expert
I'm Available

Country-wise Insights

Why is the United States Market Booming?

“Rising Prevalence of Trichomoniasis”

The United States accounted for around 34.0% market share in the global market in 2022.

The most common non-viral STI in the United States is T. vaginalis.

  • According to Centers for Disease Control and Prevention (CDC) 2021, the prevalence of t. vaginalis in the U.S. population is 2.1% in females and 0.5% in males, with black females and males having the greatest rates (9.6% and 3.6%, respectively), as opposed to non-Hispanic white women (0.8%) and Hispanic women (1.4%). contrary to chlamydia and gonorrhoea, T. vaginalis prevalence rates are comparable for women over and under the age of 24.

Hence, rising incidences of trichomoniasis in the country are raising awareness about testing kits, which are driving the market in the country.

How is China Emerging as a Prominent Market?

“Epidemic of Sexually Transmitted Diseases in China Caused by COVID-19”

China held a market share of about 9.6% of the global market in 2022.

COVID-19 had a significant but temporary impact on China's STD epidemic. Effective COVID-19 control is critical for STD prevention. Pandemic regulations designed to prevent and control COVID-19 had an impact on the daily prevention and control of other infectious diseases in China, particularly sexually transmitted diseases (STDs).

During the COVID-19 epidemic, STD control became a secluded corner of the country that was overlooked. Various recent studies stated that the COVID-19 epidemic and the control policies implemented during the lockdown period may have an impact on the STD epidemic, which has caused a high burden on public health and related medical services in China.

Thus, the above mentioned factor is facilitating the market to grow.

Will the Germany Be a Lucrative Market for Trichomonas Rapid Testing?

“Government Initiatives to Combat the Sexually Transmitted Infection”

The Germany market held around 8.1% share of the global market in 2022.

The Global Antibiotic Research and Development Partnership (GARDP) will receive an additional EUR 50 million in financing from the German Federal Ministry of Education and Research over the following five years (2023–2027). The funding from Germany will allow GARDP to create novel drug-resistant illness therapies and make sure that anybody who needs them can access them.

The declaration was made in Berlin during the World Health Conference. A number of urgent public health issues are addressed by GARDP. These include severe bacterial infections in adults, such as gonorrhoea, which affects 82 million people annually and disproportionately affects women, new-born and child sepsis, and STIs like gonorrhoea. Thus, the above mentioned reason is expanding the demand for trichomonas rapid testing.

Category-wise Insights

Which Product Type is in Greater Demand On the Global Market?

"Rapid Reaction and Quick Result Time of Rapid Test Strip”

The rapid test strip is holding around 37.8% share of the total market in 2022.

A rapid test strip is widely use as it is quick detection method that relies on visual or quantitative analysis of the results displayed in colour, fluorescence, or magnetic change after the specially formulated test strip interacts with the sample to be tested. It is also very simple to use, as the test substance is simply dropped onto the strip or immersed in the test solution. As a result, without any training, operators could easily master the testing.

Which Sample Is Most Commonly Used for Testing?

“Effective Identification of Urethra Infections using Uretheral Swabs”

Vaginal/Urethra Swab held around 79.2% of the sample segment in the market.

A vaginal or urethra swab is a used for collecting a sample of vaginal discharge for microscopy, culture, and sensitivity testing. Vaginal swab tests are commonly used to detect vaginal infections such as candidiasis, bacterial vaginosis, and trichomonas vaginalis. Trichomoniasis Infections are most commonly found in the lower genital tract. This includes the vulva, vagina, and cervix in women. It most commonly infects the urethra, a tube that drains urine from the body, in men.

Which End User is Widely Adopted the in the Market?

“Numerous Methods for Test available in Diagnostic Laboratories”

Diagnostic laboratories held around 36.7% share of the total market in 2022.

The increased prevalence of STIs and STDs has resulted in the expansion of the healthcare industry, including an increase in the number of diagnostic centres. This has increased the demand for Trichomonas rapid testing in diagnostic laboratories.

As a result, numerous diagnostic methods available in diagnostic laboratories are assisting in segment leadership.

Competition Landscape

The trichomonas rapid testing market is fragmented, and there are many sizeable rivals. The top firms are seen utilising a range of strategies, including alliances, product launches, and joint ventures, among others to increase their market positions.

Some key instances of development include:

  • On May 20, 2022, BD (Becton, Dickinson and Company), a leading global provider of medical technology, announced the launch of their brand-new molecular diagnostics platform for infectious diseases in the United States. It is a frequent test for detecting the three most prevalent non-viral STIs, including Trichomonas vaginalis, Chlamydia trachomatis, and Neisseria gonorrhoeae (TV).
  • On May 4, 2022, Abbott declared that the FDA has approved their Alinity STI Assay. The examination simultaneously identifies and distinguishes four prevalent STDs (STIs). Untreated STIs can result in serious health issues, such as an increased chance of developing certain malignancies and infertility.

Similarly, the team at Persistence Market Research has tracked recent developments related to companies in the Trichomonas Rapid Testing market, which are available in the full report.

Trichomonas Rapid Testing Industry Report Scope



Forecast Period

2023 to 2033

Historical Data Available for

2014 to 2022

Market Analysis

  • USD Million for Value
  • Units for Volume

Key Countries Covered

  • United States
  • Canada
  • Brazil
  • Argentina
  • Mexico
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • India
  • Thailand
  • Malaysia
  • Indonesia
  • China
  • Japan
  • South Korea
  • Australia
  • New Zealand
  • Türkiye
  • GCC
  • North Africa
  • South Africa

Key Market Segments Covered

  • Product
  • Sample
  • End User
  • Region

Key Companies Covered

  • Sekisui Diagnostics
  • Cepheid
  • Quidel Corporation
  • Becton, Dickinson and Company
  • Hologic, Inc.
  • Creative Diagnostics
  • Abbott
  • Koroglu Medical Devices
  • Nal Von Minden GmbH
  • Common Sense
  • Jei Daniel Biotech Corp
  • Nanjing Liming Bio-Products Co.,Ltd

Report Coverage

  • Market Forecast
  • Competition Intelligence
  • DROT Analysis
  • Market Dynamics and Challenges
  • Strategic Growth Initiatives

Customization & Pricing

Available upon Request

Key Segments Covered in Trichomonas Rapid Testing Industry Research


  • Cassette Rapid Test Kit
  • Rapid Test Strip
  • Rapid test Swab
  • Molecule based rapid test device


  • Vaginal/Urethra Swab
  • Urine

End User:

  • Hospitals
  • Diagnostic Laboratories
  • Specialty Clinics
  • Others


  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East and Africa

- Companies Covered in This Report -

  • Upper Echelon Products
  • Sekisui Diagnostics
  • Cepheid
  • Quidel Corporation
  • Becton, Dickinson and Company
  • Hologic, Inc.
  • Creative Diagnostics
  • Abbott
  • Koroglu Medical Devices
  • Nal Von Minden GmbH
  • Common Sense
  • Jei Daniel Biotech Corp
  • Nanjing Liming Bio-Products Co.,Ltd

- Frequently Asked Questions -

The global market is currently valued at around US$ 420.9 Million in 2022.

The global market estimates for 2023 is around US$ 442.4 Million in 2023.

The global market is set to reach valuation of US$ 724.5 Million by the end of 2033.

Sales of the market are set to witness growth at a CAGR of 5.1% between 2023 and 2033.

Demand for the global market increased at a 4.1% CAGR from 2014–2022.

The U.S., China, Germany, U.K., and Japan account for demand within the market, currently holding around 65.8% market share.

The U.S. accounts for around 34.0% share of the global market in 2022.

The German market held a share of about 8.1% in the global trichomonas rapid testing market in 2022.

The trichomonas rapid testing market in China held around 9.6% market share in 2022.

This site uses cookies, including third-party cookies, that help us to provide and improve our services. Privacy Policy
Google translate